# Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa

> **NCT01577368** · PHASE3 · COMPLETED · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 76 (actual)

## Conditions studied

- Pseudomonas Aeruginosa Infection

## Interventions

- **DRUG:** Piperacillin-Tazobactam continuous infusion
- **DRUG:** Piperacillin-Tazobactam intermittent infusion

## Key facts

- **NCT ID:** NCT01577368
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-01
- **Final completion:** 2014-08
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2014-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577368, "Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01577368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*